Fatty Liver Disease

According to published studies, individuals with high genetic risk have over 3 times the likelihood of developing hepatocellular carcinoma (HCC). When combined with obesity, the risk can increase to more than 5 times compared to the general population¹.

The GENOSOPHY® genetic test analyzes 14 genetic variants, offering valuable insights into disease prevention, risk prediction, and personalized management.

Who Should Consider This Test?

This test is recommended for: • Individuals already diagnosed with fatty liver disease, seeking precise genetic evaluation of the risk of progression
• People at elevated risk, such as those with family history, obesity, type 2 diabetes, or metabolic syndrome

Clinical Benefits of the GENOSOPHY® Polygenic Risk Score

Diagnosis

• Identification of individuals with increased genetic predisposition to non-alcoholic fatty liver disease (NAFLD) and its complications
• Supports early medical intervention and closer monitoring

Prognosis

• Accurate estimation of the risk of developing advanced liver damage such as fibrosis, cirrhosis, or hepatocellular carcinoma (HCC)

Management

• Personalized lifestyle and dietary strategies to reduce risk and support liver health
• Targeted prevention and monitoring for high-risk individuals

Test Procedure

1. Saliva sample collection
2. Analysis of 14 genetic variants and calculation of risk using GENOSOPHY®’s award-winning algorithm
3. Results delivered within 5–6 weeks

Additional Services

Based on each individual’s genetic profile, GENOSOPHY® also offers:
• Genetic counseling
• Tailored nutritional planning
• Dietary consulting for risk reduction

Key Reference

1. Bianco et al., Journal of Hepatology 2021;74(4):775–782
   DOI: 10.1016/j.jhep.2020.11.024